Aclarion (NASDAQ:ACON) Stock Price Down 2.2% – Here’s What Happened

Aclarion, Inc. (NASDAQ:ACON) shares traded down 2.2% during mid-day trading on Friday . The company traded as low as $5.91 and last traded at $6.20. 183,996 shares changed hands during mid-day trading, an increase of 131% from the average session volume of 79,589 shares. The stock had previously closed at $6.34.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Aclarion currently has a consensus rating of “Sell”.

Aclarion Stock Down 2.2%

The business’s fifty day moving average is $6.99 and its 200-day moving average is $7.27. The company has a market cap of $4.15 million, a PE ratio of -0.41 and a beta of 1.43.

Aclarion (NASDAQ:ACON) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($2.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29). Aclarion had a negative net margin of 10,908.50% and a negative return on equity of 67.53%. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Analysts forecast that Aclarion, Inc. will post -263.33 EPS for the current fiscal year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.